PDCD1LG2 and head and neck cancer: PD-L2 expression has been previously recognized as a biomarker of host immune responses in melanoma34, and PD-L2 expression was also predictor of positive clinical responses to anti-PD-1/Keytruda in the Keynote-12 trial for head and neck cancer patients with recurrent or metastatic disease12.